Heterodimers of glutamic acid
AssigneeMolecular Insight Pharmaceuticals, Inc.
InventorsJohn W. Babich, Craig N. Zimmerman, Kevin P. Maresca
Life of this patent
Estimating the term…
Loading patent…
AssigneeMolecular Insight Pharmaceuticals, Inc.
InventorsJohn W. Babich, Craig N. Zimmerman, Kevin P. Maresca
Estimating the term…
Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR′, S, S(O)2, C(O)2, (CH2)p Z is H or C1-C4 alkyl, R′ is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted of unsubstituted when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition, Radiolabels can be incorporated into the structure through a variety of prosthetic, groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
A compound comprising (i) a glutamate-urea-lysine moiety, (ii) a tether, and (iii) a metal chelating moiety comprising a radionuclide, or a pharmaceutically acceptable salt thereof, wherein the glutamate-urea-lysine moiety is of a structure:
Dependencies are inferred from the claim text.